EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review

Attia Mustafa, Chris Kite iD, Lukasz Lagojda iD, Alexander Dallaway iD, Kamaljit Kaur Chatha, Nwe Ni Than, Eva Kassi, Ioannis Kyrou iD, Harpal S Randeva

International Journal of Molecular Sciences · 21.11.2025 · 26 (23) · 11275

DOI: 10.3390/ijms262311275 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.11.2025. Verfasst von Attia Mustafa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Co…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic hepatic disease with a rising global prevalence (25–38% of the general population). As a new term, MASLD was introduced in 2023 to replace the previous nomenclature of non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD). This new term/definition introduced changes in the diagnostic criteria and underscores the direct link between cardio-metabolic risk and this prevalent liver disease. In this context, the present review examines the clinical and pathophysiological links between MASLD and cardiovascular disease (CVD), providing a robust evidence synthesis of primarily systematic review data on the association between MASLD and coronary artery disease (CAD), atrial fibrillation (AF), and heart failure (HF). This association appears to be not only synergistic, but also independent of other known CVD risk factors, highlighting MASLD as a key cardio-metabolic risk factor that merits prompt diagnosis and treatment. The development of MASLD-related cardiovascular morbidity increases with the severity of the underlying hepatic pathology, particularly with progression to steatohepatitis and fibrosis. Notably, growing evidence highlights the links between MASLD and CVD through cardiac structural, electrical, and functional alterations that can progress to CAD, AF, and new-onset HF. Recognizing these links in clinical practice underscores the importance of early detection and multi-disciplinary management of MASLD to prevent disease progression and CVD complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesFatty LiverNon-alcoholic Fatty Liver DiseaseHumansRisk Factors

Stichwörter der Autor:innen

MAFLDMASLDNAFLDatrial fibrillationcardiovascular diseasecoronary artery diseaseheart failuremetabolic dysfunction-associated fatty liver diseasemetabolic dysfunction-associated steatotic liver diseasenon-alcoholic fatty liver disease

Autor:innen und Institutionen

  • Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
  • Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
  • Internal Medicine Department, Faculty of Medicine, Omar Al Mukhtar University, Al-Bayda P.O. Box 919, Libya.
  • Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
  • School of Health and Wellbeing, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
  • Division of Public Health, Sport and Wellbeing, Faculty of Health, Medicine and Society, University of Chester, Chester CH1 4BJ, UK.

ORCID-Profile: Chris Kite, Lukasz Lagojda, Alexander Dallaway, Ioannis Kyrou

Zitieren

APA

Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Chatha, K. K., Than, N. N., Kassi, E., Kyrou, I., & Randeva, H. S. (2025). Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. International Journal of Molecular Sciences, 26(23), 11275. https://doi.org/10.3390/ijms262311275

Vancouver

Mustafa A, Kite C, Lagojda L, Dallaway A, Chatha KK, Than NN, et al. Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. International Journal of Molecular Sciences. 2025;26(23):11275. doi:10.3390/ijms262311275

BibTeX
@article{Mustafa2025,
  author = {Mustafa, Attia and Kite, Chris and Lagojda, Lukasz and Dallaway, Alexander and Chatha, Kamaljit Kaur and Than, Nwe Ni and Kassi, Eva and Kyrou, Ioannis and Randeva, Harpal S},
  title = {Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {23},
  pages = {11275},
  doi = {10.3390/ijms262311275}
}
Kostenlos starten →